Natural products for chemopreventive and adjunctive therapy in oncologic disease

Nutrition and Cancer

Volumn 61, Issue 5, 2009, Pages 587-597

  Dennis, Tiffany ^a   Fanous, Michael ^a   Mousa, Shaker ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMNESTEEN; ASCORBIC ACID; BETA CAROTENE; CALCIUM; CISPLATIN; COLESTIPOL; COLESTYRAMINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETRETIN; ETRETINATE; HERBACEOUS AGENT; IRINOTECAN; ISOTRETINOIN; LOPERAMIDE; LYCOPENE; NATURAL PRODUCT; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PIRARUBICIN; PROBIOTIC AGENT; RESVERATROL; RETINOIC ACID; RETINOL; SELENIUM; STARCH; TARGENTIN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; WARFARIN; ZINC;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADENOMA; ALOPECIA; ALTERNATIVE MEDICINE; ANEMIA; ANOREXIA; ANXIETY DISORDER; BACKACHE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLEEDING; BLURRED VISION; BONE MARROW SUPPRESSION; BONE PAIN; BONE SWELLING; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CANCER PREVENTION; CANCER THERAPY; CHEMOPROPHYLAXIS; CHILL; CHORIOCARCINOMA; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONFUSION; CONSTIPATION; COUGHING; DEHYDRATION; DEPRESSION; DIAPHORESIS; DIARRHEA; DIET THERAPY; DIZZINESS; DRUG HALF LIFE; DYSPNEA; EDEMA; ENDOCRINE DISEASE; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FIBROMA; FLATULENCE; FLUID RETENTION; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; GRANULOCYTOPENIA; HEAD AND NECK CARCINOMA; HEADACHE; HEART RATE; HISTIOCYTOSIS; HODGKIN DISEASE; HUMAN; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; KAPOSI SARCOMA; KIDNEY CARCINOMA; LEUKEMIA; LEUKOPENIA; LIVER CANCER; LIVER CARCINOGENESIS; LUNG CANCER; LUNG CARCINOGENESIS; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALAISE; MOTOR DYSFUNCTION; MOUTH CANCER; MUCOSA INFLAMMATION; MUSCLE CRAMP; MYALGIA; MYCOSIS FUNGOIDES; NAIL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NEPHROBLASTOMA; NEPHROLITHIASIS; NEPHROTOXICITY; NERVOUSNESS; NEUROBLASTOMA; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; OVARY CANCER; PAIN; PANCREAS CANCER; PERIPHERAL NEUROPATHY; POLYP; POTASSIUM BLOOD LEVEL; PRECANCER; PROMYELOCYTIC LEUKEMIA; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; QUALITY CONTROL; RASH; REVIEW; RHABDOMYOSARCOMA; RHINITIS; SEPSIS; SIDE EFFECT; SKIN CANCER; SKIN CARCINOGENESIS; SMALL INTESTINE CANCER; SODIUM URINE LEVEL; SPERMATOZOON MOTILITY; STOMACH ACID SECRETION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMATITIS; TEA; TESTIS CARCINOMA; THROMBOCYTOPENIA; ULCER; UNSPECIFIED SIDE EFFECT; URINE VOLUME; UTERINE CERVIX CANCER; VASODILATATION; VITAMIN SUPPLEMENTATION; VOMITING; WEAKNESS; WEIGHT REDUCTION;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL PRODUCTS; DIETARY SUPPLEMENTS; HUMANS; NEOPLASMS; PHYTOTHERAPY;

EID: 70449640536     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580902825530     Document Type: Review

References (66)

1. Cassileth B R and Deng G: Complementary and alternative therapies for cancer. Oncologist 9, 80-89, 2004.
2. Hyodo H, Eguchi K, Nishina T, Endo H, Tanimizu M, et al.: Perceptions and attitudes of clinical oncologists on complementary and alternative medicine: a nationwide survey in Japan. Cancer 97, 2861-2868, 2003.
3. National Center for Nutritional Supplements. The use of nutritional supplements in the United States. Bethesda, MD: 2007 May [cited 2007 June]. Available at http://ncNutritionalsupplements.nih.gov/news/ Nutritionalsupplementssurvey fs1.htm
4. Dy G K, Bekele L, Hanson L J, Furth A, Mandrekar S, et al.: Nutritional supplements use by patients enrolled onto phase I clinical trials. J Clin Oncol 22, 4810-4815, 2004.
5. Ernst E and Cassileth BR: The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 83, 777-782, 1998.
6. Tascilar M, De Jong F A, Verweij J, and Matheijssen R H J: Nutritional supplements during cancer treatment: beyond innocence. Oncologist 11, 732-741, 2006.
7. Molassiotis A, Fernandez-Ortega P, Pud D, et al.: Use of nutritional supplements in cancer patients: a European survey. Ann Oncol 16, 655-663, 2005. (Pubitemid 40613334)
8. Cui Y, Shu X O, Gao Y, Wen W, Ruan Z X, et al.: Use of nutritional supplements by Chinese women with breast cancer. Breast Cancer Res Treat 85, 263-270, 2004. (Pubitemid 38987261)
9. Patterson R E, Neuhouser M L, Hedderson M M, Schwartz S M, Standish L J, et al.: Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med 8, 477-485, 2002.
10. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, et al.: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280, 1569- 575, 1998.
11. NCNutritional Supplements [Internet]. Bethesda (MD): Funding Strategy: Fiscal Year 2006. 2006 [cited 2007 June 20]. Available at http:// ncNutritionalsupplements.nih.gov/research/strategy/2006.htm
12. De Smet PA: Herbal medicine in Europe-relaxing regulatory standards. N Engl J Med 352, 1176-1178, 2005.
13. Ashbury F D, Findlay H, Reynolds B, McKerracher K: A Canadian survey of cancer patients' experiences: are their needs being met? J Pain Symptom Manage 16, 298-306, 1998.
14. Cauffield JS: The psychosocial aspects of complementary and alternative therapies for cancer. Pharmacotherapy 20, 1289-1294, 2000.
15. Jian L, Xie L P, Lee A H, Binns C W: Protective effect of green tea against prostate cancer: case control study in South East China. Int J Cancer. 108, 130-135, 2004.
16. Straus S E: Herbal medicines-what's in the bottle? N Engl J Med 347, 1997-1998, 2002.
17. Cassileth B R, Lusk E J, Strouse T B, Bodenheimer B J: Contemporary unorthodox treatments in cancer medicine: a study of patients, treatments, and practitioners. Ann Intern Med 101, 105-112, 1984.
18. Vapiwala N, Mick R, DeNittis A, et al.: Initiation of complementary and alternative medical therapies by cancer patients during radiation therapy. Proc Am Soc Ther Radiat Oncol 63(1 Suppl), S451, 2005.
19. Gupta D, Lis C G, Birdsall T C: The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care. Support Care Cancer 13, 912-919, 2005.
20. Lexi-Comp Online [Internet]: Hudson (OH): Lexi-drugs. 2007 [cited 2007 Jun 6]. Available at http://online.lexi.com/crlonline
21. National Comprehensive Cancer Network [Internet]: Jenkintown (PA): NCCN Clinical Practice Guidelines in Oncology. 2007 [cited 2007 Jun 12]. Available at http://www.nccn.org/
22. Jaffe B M: Prostaglandins and cancer: an update. Prostaglandins 6, 453-461, 1974.
23. Husby G, Strickland R G, Rigler G L, Peake G T, Williams R C J r.: Direct immunochemical detection of prostaglandin-E and cyclic nucleotides in human malignant tumors. Cancer 40, 1629-1642, 1977.
24. Lupulescu A: Enhancement of carcinogenesis by prostaglandins. Nature 272, 634-636, 1978.
25. Sheng H, Shao J,Morrow JD, Beauchamp RD, DuBois RN:Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58, 362-366, 1998.
26. Thun M J: NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am 25, 333-348, 1996.
27. Moon R C,Kelloff G J,Detrisac C J, Steele VE,Thomas C F, et al.:Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxi Nutritional supplements. Carcinogenesis 14, 1487-1489, 1993.
28. Giardiello F M, Hamilton S R, Krush A J, Piantadosi S, Hylind L M, et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328, 1313-1316, 1993.
29. Steele VE,Hawk ET,Viner JL, and LubetRA: Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 523-524, 137-144, 2002.
30. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, et al.: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705-716, 1998.
31. Shiff S J, Koutsos M I , Qiao L, Rigas B: Non-steroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 222, 179-188, 1996. (Pubitemid 26043724)
32. Marnett LJ: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52, 5575-5589, 1992.
33. Physician's Desk Reference. Montvale, NJ: Thomson Reuters, Inc., 2009.
34. Xu X J, Shi S W, Tang Y M, et al.: Long-term follow-up of treatment outcome and prognosis on 46 childrenwith acute promyelocytic leukemia. Zhongguo Dang Dai Er Ke Za Zhi 9, 28-33, 2007.
35. Jagdeo J,Campbell R, Long T, Muglia J, TelangG, et al.: Sweet's syndromelike neutrophilic lobular panniculitis associated with all-trans-retinoic acid chemotherapy in a patient with acute promyelocytic leukemia. J Am Acad Dermatol 56, 690-693, 2007.
36. Delia P, Sansotta G, Donato V, Frosina P,Messina G, et al.:Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 13, 912-915, 2007. (Pubitemid 46470303)
37. Le Leu R K, Brown I L, Hu Y, Bird A R, Jackson M, et al.: A symbiotic combination of resistant starch and Bifidobacterium lactis facilitates apoptotic deletion of carcinogen-damaged cells in rat colon. J Nutr 135, 996-1001, 2005.
38. Natural Standard: The Authority on Integrative Medicine [Internet]. Nutritional supplements bridge. 2007 [cited 2007 Jun 12]. Available at http://www.naturalstandard.com/
39. Kiefer I, Prock P, Lawrence C, Wise J, Bieger W, et al.: Supplementation with mixed fruit and vegetable juice concentrates increased serum antioxidants and folate in healthy adults. J Am Coll Nutr 23, 205-211, 2004.
40. Peters U, Foster C B, Chatterjee N, Schatzkin A, Reding D, et al.: Serum selenium and risk of prostate cancer-a nested case-control study. Am J Clin Nutr 85, 209-217, 2007.
41. Sakoda LC, Graubard B I, Evans A A, London W T, Lin W Y, et al.: Toenail selenium and risk of hepatocellular carcinoma mortality in Haimen City. Int J Cancer 115, 618-624, 2005.
42. Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, et al.: The SU.VI.MAX study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 164, 2335-2342, 2004.
43. Lambert J D and Yang C S: Proceedings of the third international Scientific Symposium on Tea and Human Health: role of flavonoids in the diet: mechanisms of cancer prevention by tea constituents. J Nutr 133, 3262S- 3267S, 2003.
44. Mukhtar H and Ahmad N: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 71(Suppl), 1698S-1702S, 2000.
45. Fujiki H, Suganuma M, Okabe S, Sueoka E, Suga K, et al.: Mechanistic findings of green tea as cancer preventive for humans. Proc Soc Exp Biol Med 220, 225-228, 1999.
46. Masuda M, Suzui M, Lim J T E, and Weinstein I B: Epigallocatechin-3- gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res 9, 3486-3491, 2003.
47. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H, et al.: Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 98, 10350-10355, 2001.
48. Jung Y D, Kim M S, Shin B A, Chay K O, Ahn B W, et al.: EGCG, a major component of green tea, inhibits tumor growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 84, 844-850, 2001.
49. Sadzuka Y, Sugiyama T, and Sonobe T: Efficacies of tea components on doxorubicin induced antitumor activity and reversal ofmultidrug resistance. Toxicol Lett 114, 155-162, 2000.
50. Stewart JR, Artime MC, and O'Brian CA: Resveratrol: a candidate nutritional substance for prostate cancer prevention. J Nutr 133, 2440S-2443S, 2003.
51. Walle T, Hsieh F, DeLegge M: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32, 1377-1381, 2004.
52. Stewart J R, Ward N E, Ioannides C G, and O'Brian C A: Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactorindependent, arginine-rich protein substrate by a novel mechanism. Biochemistry 38, 13244-13251, 1999.
53. Bhat K P, Lantvit D, Christov K, Mehta R G, Moon R C, et al.: Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 20, 7456-7463, 2001.
54. Mitchell S H, Zhu W, andYoung C Y: Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 5892-5895, 1999. (Pubitemid 30004946)
55. Stojanovic S, Sprinz H, and Brede O: Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Arch Biochem Biophys 391, 79-89, 2001.
56. Ciolino H P and Yeh G C: Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol 56, 760-767, 1999.
57. Jang M, Cai L, Udeani G O, Slowing K V, Thomas C F, et al.: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220, 1997.
58. Tyagi A, Singh R P, Agarwal C, Siriwardana S, Sclafani R A, et al.: Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 26, 1978-1987, 2005.
59. Laio H-F, Kuo C-D, Yang Y-C: Resveratrol enhances radiosensitivity of human non-small cell lung cancer NCI-H838 cells accompanied by inhibition of nuclear factor-kappa B activation. J Radiat Res 46, 387-393, 2005.
60. Subbaramaiah K, Chung W J, Michaluart P, Telang N, Tanabe T, et al.: Resveratrol inhibits COX-2 transcription and activity in phorbol estertreated human mammary epithelial cells. J Biol Chem 273, 21875-21882, 1998
61. Gusman J, Malonne H, and Atassi G: A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22, 1111-1117, 2001.
62. Mousa A S and Mousa S A: Anti-angiogenesis efficacy of the garlic ingredient alliin and antioxidants: role of nitric oxide and p53. Nutr Cancer 53, 104-110, 2005.
63. Malik A, Afaq F, Sarfaraz S, Adhami V M, Syed D N, et al.: Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 102, 14813-14818, 2005.
64. DeSmet PA: Health risks of herbal remedies: an update. Clin Pharmacol Ther 76, 1-17, 2004.
65. Infante P F and White M C: Benzene: epidemiologic observations of leukemia by cell type and adverse health effects associated with low-level exposure. Environ Health Perspect 52, 75-82, 1983.
66. Bandera E V, Kushi L H, Moore D F, Gifkins D M, McCollough M L: Review: fruits and vegetable and endometrial cancer risk: a systematic literature review and meta-analysis. Nutr Cancer 58, 6-21, 2007.